Navigation Links
Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
Date:10/24/2007

IRVINE, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (OTC: CGCP), announced that the company will release results for its third quarter ended September 30, 2007 prior to market open on Wednesday, November 14, 2007. The company also said that President Richard P. Lanigan and Senior Vice President and Chief Financial Officer William R. Abbott will host an investor conference call that day at 12:00 p.m. Eastern time (9:00 a.m. Pacific time) to review the company's financial results and business outlook.

The call is open to all interested investors through a live audio web broadcast via the Internet at http://www.cardiogenesis.com and will also be available by dialing (888) 873-4896. The participant passcode is 14418507. The call will be archived on the company's web site and will be available for playback for seven days beginning shortly after the live webcast.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The company's market leading Holmium: YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.

For more information on the company and its products, please visit the Cardiogenesis company website at http:
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
11. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)... , TUSTIN, Calif., Dec. 4 /PRNewswire-FirstCal...PPHM ) today announced that it will release its fi...ear 2009 on December 10, 2008 at 7:00 a.m. EST and...s the results at 11:30 a.m. EST on the same day. ...uss financial results for the second quarter ended...
(Date:12/4/2008)... CITY, Dec. 4 /PRNewswire-FirstCall/ - AEterna Zen...iopharmaceutical company focused on endocrine ther...nt and CEO, Juergen Engel, Ph.D., will take part i...ay With Newer And Better Agents" at the upcoming R...ednesday, December 10, 2008 at 4:30 pm (eastern ti...
(Date:12/4/2008)...L, WA, and VANCOUVER, Dec. 4 /PRNewswire-FirstCall... ) will participate on the ,Waging a Battle Agains...althcare Conference on Thursday, December 11 at 8:...ork. During the panel discussion, OncoGenex, Presi...ill provide a brief overview of the company,s onco...
(Date:12/3/2008)... and PHILADELPHIA, Dec. 3 /PRNewswire-FirstCall/ -...day that it is waiving a condition relating to a,... offer to purchase all of,the outstanding shares ...asdaq: GNLB ), for $1.30 per share in cash witho...es. , It is a condition to the completion o...
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3
...yless to describe his vision for GE. Specifically,...t-seven-signatures-before-buying-toilet-paper, bur...imbly into markets, execute quickly on decisions, ...o well to tear a note from Welchs playbook. Why? B...fashion. Its time economic developers craft polici...
...e first through the third, will be most interestin...Germany, France, Italy, Britain, Canada and Russia...es. Unfortunately, China is missing from the party...thats a huge mistake! , ,Usually these meetings a...oin hands and smile for the huge group of assemble...
...h Heling, co-founder, SecurePipe, Inc. SecurePip...de variety of industries including manufacturing, ...mer products and technology. Heling discusses inno...ey, and ecruiting a CEO. , , WTN: Please start b...Heling (JH): In 1996, I was doing back-end Unix s...
... Governor Doyle and organized by Forward Wisconsin...echnology industrys leading conference with goals ...capital, showcase the states research and universi... has a growing biotechnology community. According ...jectives in spite of limited conference participat...
Other Biology Technology:Are We Headed for a Global Economic Collapse? 2WTN Exclusive Interview with Josh Heling 2WTN Exclusive Interview with Josh Heling 3On site at BIO 2003 2On site at BIO 2003 3On site at BIO 2003 4On site at BIO 2003 5
(Date:12/3/2008)...uke University study suggests that evolution can b...ogs depend on an energy-efficient style of four-fo...ey, cats seem to have evolved a profoundly ineffic...ird in slow motion. , "It is usually assumed tha...aniel Schmitt, a Duke associate professor of evolu...
(Date:12/3/2008)...lem of children failing to take their medication f...tackled as part of a new university research proje...lists at The University of Nottingham and The Univ...f school children with asthma, diabetes, congenita...rriers that prevent them from taking medicines pre...
(Date:12/3/2008)...mber 3, 2008 Today, the International Society for...rofessional organization of stem cell researchers,...opment of safe and effective stem cell therapies f...the Guidelines for the Clinical Translation of Ste...ember issue of Cell Stem Cell , the official affi...
(Date:12/3/2008)...s that are high in protein and cereal grains produ...e calcium excretion and weaken bones, according to...rine Society,s Journal of Clinical Endocrinology ...asing the alkali content of the diet, with a pill ...s the opposite effect and strengthens skeletal hea...
Breaking Biology News(10 mins):Dogs chase efficiently, but cats skulk counterintuitively 2A spoonful of sugar? 2A spoonful of sugar? 3The International Society for Stem Cell Research releases new guidelines 2The International Society for Stem Cell Research releases new guidelines 3Calcium and vitamin D may not be the only protection against bone loss 2Intercim Launches Pertinence Suite Powered by Velocity 14544 1Intercim Launches Pertinence Suite Powered by Velocity 14544 2Intercim Launches Pertinence Suite Powered by Velocity 14544 3Intercim Launches Pertinence Suite Powered by Velocity 14544 4TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 1TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 4Peapod Offers First Ever Virtual Nutritionist 14537 1Peapod Offers First Ever Virtual Nutritionist 14537 2OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 1OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 2OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 3OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 4
...ersity of Wisconsin-Milwaukee, a Wisconsin biotech...found in jellyfish is neuro-protective and may be ..., Testing of aequorin has yielded promising result...ated in Madison. Researcher James Moyer, Jr., an a...n cells to the "lab" equivalent of a stroke, and m...
..."switch gene" in two groups of microscopic plankto...hether certain marine plankton convert a sulfur co...e it can affect the earth,s temperature, or remain... "This new gene offers a powerful tool to study th... sulfur exchange between the ocean and atmosphere,...
...s sack of chemicals and a living cell? It,s all in...biophysical chemist Steven Boxer. With colleagues ...d Lawrence Livermore National Laboratory, he has d...edented resolution-on the order of 100 nanometers,... smaller than entire cells. Understanding the chem...
... the National Cancer Institute, a Wake Forest Univ... to improve the effectiveness of a drug that he d..., Waldemar Debinski, M.D., Ph.D., pioneered a met...BM) with less damage to healthy cells. The drug is...inski is working on its fourth generation in the l...
Other Biology News:UWM brain research supports drug development from jellyfish protein 2Bacterial 'switch gene' regulates how oceans emit sulfur into atmosphere 2With record resolution and sensitivity, tool images how life organizes in a cell membrane 2With record resolution and sensitivity, tool images how life organizes in a cell membrane 3With record resolution and sensitivity, tool images how life organizes in a cell membrane 4With record resolution and sensitivity, tool images how life organizes in a cell membrane 5With record resolution and sensitivity, tool images how life organizes in a cell membrane 6Scientist works to improve treatment for brain tumors 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,518-2) or contact custom
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,517-4) or contact custom
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /
Biology Products: